Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Massimo Gentile, Tait D Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni TripepiKari G Chaffee, Parikh A Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E Kay, Aaron Polliack, Robin Foà, Fortunato Morabito

Research output: Contribution to journalArticle

Abstract

An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume101
Issue number5
Early online dateJul 24 2018
DOIs
Publication statusPublished - 2018

    Fingerprint

Cite this

Gentile, M., Shanafelt, T. D., Mauro, F. R., Reda, G., Rossi, D., Laurenti, L., Del Principe, M. I., Cutrona, G., Angeletti, I., Coscia, M., Herishanu, Y., Chiarenza, A., Molica, S., Ciolli, S., Goldschmidt, N., Angrilli, F., Giordano, A., Rago, A., Bairey, O., ... Morabito, F. (2018). Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. European Journal of Haematology, 101(5). https://doi.org/10.1111/ejh.13149